African genomics company, 54gene has secured $15 million Series A round to scale operations in support of generating novel insights from human genetics research that result in high impact discoveries for improving human health through therapeutic development.
The funding is led by Adjuvant Capital,
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
